TY - JOUR
T1 - Obstructive sleep apnea, other sleep characteristics, and risk of CKD in the Atherosclerosis Risk in Communities sleep heart health study
AU - Full, Kelsie M.
AU - Jackson, Chandra L.
AU - Rebholz, Casey M.
AU - Matsushita, Kunihiro
AU - Lutsey, Pamela L.
N1 - Publisher Copyright:
Copyright © 2020 by the American Society of Nephrology
PY - 2020/8
Y1 - 2020/8
N2 - Background Obstructive sleep apnea may be associated with development of CKD through hypoxia, inflammation, and oxidative stress. Individuals with this sleep disorder are also at increased risk for established CKD risk factors, including obesity, hypertension, and type 2 diabetes. Methods We examined the association between obstructive sleep apnea, other sleep characteristics, and risk of incident CKD (stage 3 or higher) in 1525 participants (mean age, 62.5 years; 52.4% women) in the Atherosclerosis Risk in Communities (ARIC) study who completed in-home polysomnography assessments. We used the apnea-hypopnea index (events per hour) to define obstructive sleep apnea severity (normal,,5.0; mild, 5.0–14.9; moderate, 15.0–29.9; and severe, $30.0) and defined incident CKD (stage 3 or higher) as eGFR,60 ml/min per 1.73 m2 and $25% decline from baseline, CKD-related hospitalization or death, or ESKD. Cox proportional hazards regression was used to estimate obstructive sleep apnea severity with risk of incident CKD, adjusting for demographics, lifestyle behaviors, and cardiometabolic conditions. Results During 19 years (median) of follow-up, 461 CKD events occurred. After adjustment for demographics and lifestyle behaviors, severe obstructive sleep apnea associated with increased risk of CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.08 to 2.10), which was attenuated after adjustment for body mass index (HR, 1.07; 95% CI, 0.75 to 1.52). No other sleep characteristics associated with incident CKD. Conclusions We found a link between obstructive sleep apnea and an elevated risk of stage 3 CKD or higher, but this association was no longer significant after adjusting for obesity, a risk factor for both conditions. Given the high prevalence of obstructive sleep apnea and CKD among adults, further investigation is warranted.
AB - Background Obstructive sleep apnea may be associated with development of CKD through hypoxia, inflammation, and oxidative stress. Individuals with this sleep disorder are also at increased risk for established CKD risk factors, including obesity, hypertension, and type 2 diabetes. Methods We examined the association between obstructive sleep apnea, other sleep characteristics, and risk of incident CKD (stage 3 or higher) in 1525 participants (mean age, 62.5 years; 52.4% women) in the Atherosclerosis Risk in Communities (ARIC) study who completed in-home polysomnography assessments. We used the apnea-hypopnea index (events per hour) to define obstructive sleep apnea severity (normal,,5.0; mild, 5.0–14.9; moderate, 15.0–29.9; and severe, $30.0) and defined incident CKD (stage 3 or higher) as eGFR,60 ml/min per 1.73 m2 and $25% decline from baseline, CKD-related hospitalization or death, or ESKD. Cox proportional hazards regression was used to estimate obstructive sleep apnea severity with risk of incident CKD, adjusting for demographics, lifestyle behaviors, and cardiometabolic conditions. Results During 19 years (median) of follow-up, 461 CKD events occurred. After adjustment for demographics and lifestyle behaviors, severe obstructive sleep apnea associated with increased risk of CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.08 to 2.10), which was attenuated after adjustment for body mass index (HR, 1.07; 95% CI, 0.75 to 1.52). No other sleep characteristics associated with incident CKD. Conclusions We found a link between obstructive sleep apnea and an elevated risk of stage 3 CKD or higher, but this association was no longer significant after adjusting for obesity, a risk factor for both conditions. Given the high prevalence of obstructive sleep apnea and CKD among adults, further investigation is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85089126591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089126591&partnerID=8YFLogxK
U2 - 10.1681/ASN.2020010024
DO - 10.1681/ASN.2020010024
M3 - Article
C2 - 32591438
AN - SCOPUS:85089126591
SN - 1046-6673
VL - 31
SP - 1859
EP - 1869
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 8
ER -